Eli Lilly and Company (LLY) Shares Sold by Sapphire Star Partners LP
Sapphire Star Partners LP lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 26.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,319 shares of the company’s stock after selling 3,981 shares during the period. Eli Lilly and comprises 1.3% of Sapphire Star Partners LP’s portfolio, making the stock its 21st largest holding. Sapphire Star Partners LP’s holdings in Eli Lilly and were worth $968,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC raised its position in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new position in Eli Lilly and during the second quarter worth about $128,000. San Francisco Sentry Investment Group CA acquired a new position in Eli Lilly and during the second quarter worth about $129,000. Point72 Asia Hong Kong Ltd raised its position in Eli Lilly and by 237.4% during the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after acquiring an additional 1,239 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. acquired a new position in Eli Lilly and during the second quarter worth about $148,000. 76.42% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Eli Lilly and Company (NYSE LLY) traded up $0.22 during mid-day trading on Tuesday, reaching $86.67. 3,336,800 shares of the company traded hands, compared to its average volume of 3,672,243. Eli Lilly and Company has a 1 year low of $67.42 and a 1 year high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $95,189.66, a price-to-earnings ratio of 21.14, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.60%. Eli Lilly and’s dividend payout ratio is 98.58%.
In related news, major shareholder Lilly Endowment Inc sold 190,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the completion of the transaction, the insider now owns 123,682,287 shares of the company’s stock, valued at $10,207,499,146.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold 628,588 shares of company stock valued at $53,399,536 in the last ninety days. 0.20% of the stock is currently owned by company insiders.
A number of equities analysts have issued reports on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, December 5th. Morgan Stanley lifted their target price on shares of Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 21st. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Berenberg Bank restated a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research report on Thursday, October 26th. Finally, Leerink Swann lifted their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $90.25.
TRADEMARK VIOLATION NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/12/eli-lilly-and-company-lly-shares-sold-by-sapphire-star-partners-lp.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.